Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivomouse colon cancer model

BMC Cancer

Table 5 The influence of PRI-2191 or PRI-2205 alone or in combination with 5-FU on intestinal tumor growth, leukocytes and platelets in the blood samples from mice with MC38 colon cancer

Group	Tumor weight				Leukocytes	Platelets	N
Group	Mean ± SD [g]	TGI [%]	%H TGI	Effect	Mean ± SD [10³/μL]	Mean ± SD [10³/μL]	N
Control	1.4 ± 1.06				7.7 ± 3.4	684 ± 309	7
PRI-2191	1.26 ± 0.80	4			7.2 ± 1.4	835 ± 170	4
PRI-2205	0.86 ± 0.93	35			8.7 ± 2.3	887 ± 67	6
5-FU	0.28 ± 0.27	79			15.5 ± 5.7	1186 ± 207^**c	6
5-FU + PRI-2191	0.08 ±0.15^*a,b	94	80	Synergism	8.6 ± 3.0	1159 ± 254^**c	7
5-FU + PRI-2205	0.32 ± 0.25	75	86	Antagonism	7.6 ± 4.1	1046 ± 320	6

TGI, Tumor growth inhibition; %H TGI, Hypothetical tumor growth inhibition; N, Number of mice in group; SD, Standard deviation.
^**a P < 0.01 as compared to control; ^*b P < 0.05 as compared to PRI-2191: Kruskal-Wallis ANOVA (Multiple Comparisons p values (2-tailed)); ^**c P < 0.01 as compared to control: Tukey HSD.
Mice bearing MC38 tumors implanted i.i. were i.v. injected with 5-FU at a dose of 100 mg/kg/day on days: 8, 15 and/or vitamin D analogs: PRI-2191 at a dose of 1 μg/kg/day or PRI-2205 at a dose of 10 μg/kg/day. Both analogs were administrated s.c., three times a week from days 10 to 20. Mice were sacrificed on day 22 after i.i. transplantation, tumors were weighed and blood was collected.

ISSN: 1471-2407